Related Experiment Video
Updated: Dec 25, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter
Christopher Del Prete1, Christopher G Azzoli2
1Department of Medicine, Division of Hematology/Oncology,Warren Alpert Medical School of Brown University, Providence, RI.
Abstract:
The diagnosis and treatment of lung cancer is entering a new era. With increasingly advanced diagnostic tools, we are more able than ever to pinpoint genetic changes in tumor cells that allow us to treat with highly effective, targeted therapy. In a growing number of patients, we are able to avoid cytotoxic therapies altogether. The recent advent of immunotherapy has led to a similar paradigm shift. This article will review the latest advances in tumor tissue and blood biomarkers directly as they relate to available treatments. Specifically, we will review activating and sensitizing gene mutations, gene fusions, PD-L1 tumor score, and close with an appraisal of the rapidly advancing field of peripheral blood biomarkers.
Insights
Lung cancer treatment is advancing with targeted therapies and immunotherapy. Biomarker analysis, including gene mutations and PD-L1 scores, guides personalized treatment strategies, reducing the need for traditional chemotherapy.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Lung cancer diagnosis and treatment are rapidly evolving.
- Advanced diagnostic tools enable precise identification of tumor genetic alterations.
- Immunotherapy has revolutionized cancer treatment paradigms.
Purpose of the Study:
- To review the latest advances in tumor tissue and blood biomarkers.
- To correlate biomarker findings with available therapeutic options.
- To highlight the shift towards targeted and immune-based therapies in lung cancer.
Main Methods:
- Review of current literature on lung cancer biomarkers.
- Analysis of diagnostic tools for genetic mutations and fusions.
- Evaluation of PD-L1 scoring in tumor tissue.
- Assessment of peripheral blood biomarkers for lung cancer.
Main Results:
- Targeted therapies are increasingly effective for specific genetic mutations (e.g., EGFR, ALK).
- Immunotherapy, guided by PD-L1 expression, offers new treatment avenues.
- Minimally invasive blood-based biomarkers show promise for diagnosis and monitoring.
Conclusions:
- Personalized medicine in lung cancer is driven by molecular profiling.
- Biomarker-guided treatment selection improves patient outcomes and reduces toxicity.
- The future of lung cancer care involves integrated analysis of tissue and liquid biopsies.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:18Cancer